BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res 2019;81:56-61. [PMID: 31030089 DOI: 10.1016/j.leukres.2019.03.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Abraham A, Matsui W. Hedgehog Signaling in Myeloid Malignancies. Cancers (Basel) 2021;13:4888. [PMID: 34638372 DOI: 10.3390/cancers13194888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Chai JY, Sugumar V, Alshawsh MA, Wong WF, Arya A, Chong PP, Looi CY. The Role of Smoothened-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis. Biomedicines 2021;9:1188. [PMID: 34572373 DOI: 10.3390/biomedicines9091188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Fersing C, Mathias F. Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors. Acta Pharmaceutica 2022;72:9-34. [DOI: 10.2478/acph-2022-0007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ma J, Ge Z. Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. Bosn J Basic Med Sci 2021;21:409-21. [PMID: 33577442 DOI: 10.17305/bjbms.2020.5485] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Madaci L, Colle J, Venton G, Farnault L, Loriod B, Costello R. The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. Biomark Res 2021;9:50. [PMID: 34176517 DOI: 10.1186/s40364-021-00300-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Bernasconi P, Borsani O. Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal. Cancers (Basel) 2021;13:3170. [PMID: 34202000 DOI: 10.3390/cancers13133170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? Best Pract Res Clin Haematol 2021;34:101245. [PMID: 33762100 DOI: 10.1016/j.beha.2021.101245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zucenka A, Maneikis K, Pugaciute B, Ringeleviciute U, Dapkeviciute A, Davainis L, Daukelaite G, Burzdikaite P, Staras V, Griskevicius L. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients. Ann Hematol 2021;100:1195-202. [PMID: 33661333 DOI: 10.1007/s00277-021-04471-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zhou C, Du J, Zhao L, Liu W, Zhao T, Liang H, Fang P, Zhang K, Zeng H. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia. Cell Death Dis 2021;12:231. [PMID: 33658491 DOI: 10.1038/s41419-021-03504-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
10 Pagliuca S, Gurnari C, Visconte V. Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. Cancers (Basel) 2021;13:784. [PMID: 33668555 DOI: 10.3390/cancers13040784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
11 Feld J, Silverman LR, Navada SC. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases. Clin Lymphoma Myeloma Leuk 2021;21:e415-22. [PMID: 33547022 DOI: 10.1016/j.clml.2020.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Franke G, Lückemeier P, Platzbecker U. Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse. Clinical Lymphoma Myeloma and Leukemia 2021;21:1-7. [DOI: 10.1016/j.clml.2020.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
13 Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev 2021;48:100791. [PMID: 33423844 DOI: 10.1016/j.blre.2020.100791] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
14 Masters JC, LaBadie RR, Salageanu J, Li J, Shaik N. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study. Clin Pharmacol Drug Dev 2021;10:707-17. [PMID: 33356019 DOI: 10.1002/cpdd.897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bewersdorf JP, Carraway H, Prebet T. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol 2020;11:2040620720955006. [PMID: 33240476 DOI: 10.1177/2040620720955006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
16 Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K, Davainis L, Zvirblis T, Stoskus M, Gineikiene E, Norvilas R, Dirse V, Surauciute A, Zucenkiene E, Griskevicius L. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. Eur J Haematol 2021;106:105-13. [PMID: 32997830 DOI: 10.1111/ejh.13527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Tavares M, Chacim S, Mariz JM. Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. Ann Hematol 2021;100:837-9. [PMID: 33001280 DOI: 10.1007/s00277-020-04291-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Bewersdorf JP, Zeidan AM. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Expert Review of Hematology 2020;13:1131-42. [DOI: 10.1080/17474086.2020.1819233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Wolska-washer A, Robak T. Glasdegib in the treatment of acute myeloid leukemia. Future Oncology 2019;15:3219-32. [DOI: 10.2217/fon-2019-0171] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]